Drugs / navicixizumab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03035253 | Dec 2016 → Sep 2018 | colorectal cancer | OncoMed Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03030287 | Dec 2016 → Apr 2020 | fallopian tube cancer, ovarian cancer, peritoneum cancer | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02298387 | Dec 2014 → May 2017 | high grade malignant neoplasm | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05453825 | Aug 2022 → Apr 2024 | colorectal cancer, gastric cancer, ovarian cancer, triple-negative breast carcinoma | OncXerna Theraputics, Inc. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05043402 | Nov 2022 → Nov 2023 | fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma | OncXerna Theraputics, Inc. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-04-22 | Mereo BioPharma | Results Navicixizumab Phase 1b data presented in Journal of Clinical Oncology mereobiopharma.com ↗
Mereo BioPharma's partner for the development of Navicixizumab, OncXerna Therapeutics Inc. announced that Navicixizumab Phase 1b data has been published in the Journal of Clinical Oncology. |
| 2019-10-07 | Mereo BioPharma | Regulatory Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer mereobiopharma.com ↗
today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to navicixizumab |
All press releases naming this drug 5 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | navicixizumab | “PURPOSE: This phase Ib study evaluated the safety and efficacy of paclitaxel plus navicixizumab, a bispecific antiangiogenic antibody to vascular endothelial growth factor and...” PMID 35439029 ↗ Apr 2022 |
| Known as | OMP-305B83 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03035253 ↗ |
| Action | Inhibit | “OMP-305B83 may block the growth of cancer stem cells” NCT03035253 ↗ |
| Modality | Monoclonal antibody | “bispecific monoclonal antibody” NCT02298387 ↗ |
| Route | Intravenous | “intravenous (in the vein) infusions” NCT02298387 ↗ |